Teriflunomide more effective, less costly in relapsing MS in China
Clinical study
First Online:
Reference
- Xu Y, et al. Cost-effectiveness of Teriflunomide Compared to Interferon Beta-1b for Relapsing Multiple Sclerosis Patients in China. Clinical Drug Investigation : 25 Jan 2019. Available from: URL: http://doi.org/10.1007/s40261-019-00750-3
Copyright information
© Springer Nature Switzerland AG 2019